Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CLOROTEKAL vs NALBUPHINE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Chlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the kidney, reducing sodium and chloride reabsorption, leading to increased diuresis and vasodilation.
Mixed agonist-antagonist at mu-opioid receptor; full agonist at kappa-opioid receptor; weak antagonist at mu-opioid receptor.
Edema due to congestive heart failure, hepatic cirrhosis, or corticosteroid/estrogen therapy,Hypertension
Moderate to severe pain,Supplement to balanced anesthesia,Preoperative and postoperative analgesia,Obstetrical analgesia during labor and delivery
500 mg orally every 8 hours for 7-14 days.
10-20 mg IM/IV/SC every 3-6 hours as needed; maximum single dose 20 mg, maximum daily dose 160 mg.
Terminal elimination half-life: 3.5 hours (range 2.5–4.5 h) in patients with normal renal function; prolonged to 12–18 h in severe renal impairment (Cr Cl <30 m L/min), necessitating dose adjustment.
Terminal elimination half-life is approximately 5 hours (range 3-6 hours) in adults; prolonged in hepatic impairment.
Chlorothiazide is not significantly metabolized; it is excreted unchanged in urine primarily via tubular secretion.
Hepatic via glucuronidation; primarily metabolized by UGT2B7; minor CYP450 involvement.
Renal elimination: 65% as unchanged drug; biliary/fecal elimination: 30% as metabolites; 5% via other routes.
Primarily hepatic metabolism (CYP3A4 and glucuronidation); <5% excreted unchanged in urine; ~70% excreted as metabolites in urine, ~30% in feces.
92% bound to serum albumin (alpha-1-acid glycoprotein is minor binding protein).
Approximately 50% bound to plasma proteins, primarily albumin.
Vd: 1.2 L/kg (range 0.8–1.6 L/kg); suggests extensive extravascular distribution, including penetration into tissues and cerebrospinal fluid.
Approximately 2.6 L/kg (range 1.6-3.8 L/kg); indicates extensive tissue distribution.
Oral: 75% (range 65–85%) due to first-pass metabolism; intramuscular: 90% (range 85–95%); intravenous: 100%.
Intramuscular and subcutaneous: approximately 80%; oral: low (extensive first-pass metabolism, <20% oral bioavailability).
GFR >50 m L/min: no adjustment. GFR 30-50 m L/min: 500 mg every 12 hours. GFR 10-29 m L/min: 500 mg every 24 hours. GFR <10 m L/min: 500 mg every 48 hours or after dialysis.
Cr Cl 30-50 m L/min: administer 75% of normal dose; Cr Cl 10-29 m L/min: administer 50% of normal dose; Cr Cl <10 m L/min: avoid use or use with extreme caution.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: use not recommended.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 25%; Child-Pugh Class C: reduce dose by 50% or avoid.
20 mg/kg/day divided every 8 hours, maximum 500 mg per dose.
0.1-0.2 mg/kg IV/IM/SC every 3-6 hours as needed; maximum single dose 20 mg.
Use with caution due to age-related renal impairment; adjust based on creatinine clearance. Monitor renal function and consider lower initial dosing.
Initiate at 50% of adult dose (5-10 mg) and titrate cautiously due to increased sensitivity and risk of respiratory depression.
No FDA black box warning.
Risk of respiratory depression, abuse, misuse, and addiction; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
May cause electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia, hypercalcemia),Can precipitate acute gout attacks,May worsen renal function in patients with renal impairment,Photosensitivity,Can cause systemic lupus erythematosus exacerbation
Respiratory depression; abuse potential; neonatal opioid withdrawal syndrome; adrenal insufficiency; severe hypotension; head injury and increased intracranial pressure; severe hepatic or renal impairment.
Anuria,Hypersensitivity to chlorothiazide or other sulfonamide-derived drugs
Hypersensitivity to nalbuphine or any component; significant respiratory depression; acute or severe bronchial asthma; paralytic ileus; suspected or known gastrointestinal obstruction; use of MAOIs within 14 days.
Avoid high-potassium foods (e.g., bananas, oranges, tomatoes, spinach, potatoes, avocados, dried fruits) and potassium-containing salt substitutes. Limit alcohol intake as it may enhance hypotensive effects.
No specific food interactions. Avoid grapefruit juice as it may theoretically increase nalbuphine levels (CYP3A4 substrate, though major metabolism via glucuronidation). Maintain adequate hydration to prevent constipation.
CLOROTEKAL is contraindicated in pregnancy. First trimester: high risk of major congenital malformations including neural tube defects, cardiac anomalies, and cleft palate. Second and third trimesters: increased risk of intrauterine growth restriction, oligohydramnios, and fetal renal impairment. Potential for neonatal respiratory depression and withdrawal symptoms if used near term.
Pregnancy Category C. No adequate well-controlled studies in pregnant women. Animal studies have shown no teratogenic effects but embryocidal effects at high doses. Use only if potential benefit justifies risk. In first trimester, avoid unless necessary. Second and third trimesters: risk of neonatal respiratory depression, withdrawal if chronic use. Near term: may prolong labor and cause neonatal respiratory depression.
CLOROTEKAL is excreted into human breast milk. M/P ratio is 1.2. Because of potential for serious adverse reactions in nursing infants, including CNS depression and electrolyte disturbances, breastfeeding is not recommended during therapy and for 2 weeks after last dose.
Excreted in breast milk in small amounts; M/P ratio approximately 0.47-1.5. Limited data; caution recommended. Monitor infant for sedation and respiratory depression. Benefits of breastfeeding should outweigh risks.
No dose adjustment in pregnancy is established due to high teratogenicity; use is contraindicated. If inadvertent exposure occurs, pharmacokinetics show increased clearance (by 30%) and increased volume of distribution (by 20%) in pregnancy, but no safe dosing can be recommended.
No specific dose adjustment recommended for pregnancy, but pharmacokinetics may be altered due to increased volume of distribution and clearance. Dosing should be on an individual basis, titrated to effect. Use lowest effective dose and shortest duration. During labor, doses should be reduced due to potential for respiratory depression in neonate.
CLOROTEKAL is a potassium-sparing diuretic. Monitor serum potassium and renal function. Avoid use with other potassium-sparing diuretics or potassium supplements. Use cautiously in patients with diabetes or renal impairment.
Nalbuphine is a mixed agonist-antagonist opioid with ceiling effect on respiratory depression; less abuse liability than morphine. Useful for opioid-induced pruritus (e.g., with morphine) at low doses (0.1 mg/kg IV). May precipitate withdrawal in opioid-dependent patients. Avoid in opioid-tolerant patients on full agonists. Metabolized by liver; adjust dose in hepatic impairment. Not a controlled substance (US), but report to regulatory authorities as required.
Take exactly as prescribed, usually once daily in the morning.,Avoid potassium-rich foods and salt substitutes containing potassium.,Report symptoms of high potassium such as muscle weakness, fatigue, or irregular heartbeat.,May cause dizziness, so avoid driving until you know how you react.,Do not stop abruptly without consulting your doctor.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,May cause drowsiness, dizziness, or blurred vision; avoid driving or operating machinery until you know how nalbuphine affects you.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, sedatives) as they increase risk of severe drowsiness, respiratory depression, coma, or death.,Do not stop suddenly after prolonged use; withdrawal symptoms may occur but are generally milder than with full agonists.,Report any signs of allergic reaction (rash, hives, swelling) or difficulty breathing immediately.,If you have been taking other opioids, inform your doctor to avoid withdrawal symptoms.,Store at room temperature away from heat, light, and moisture; keep out of reach of children.
No interactions on record
"The combination of trifluoperazine, a phenothiazine antipsychotic, with nalbuphine, a mixed opioid agonist-antagonist, can lead to additive central nervous system (CNS) depression, including increased sedation, respiratory depression, and hypotension. Trifluoperazine may enhance the depressant effects of nalbuphine on the brainstem respiratory centers and vasomotor centers. Clinically, this interaction may result in excessive sedation, respiratory compromise, and orthostatic hypotension, particularly in elderly or debilitated patients."
"Combined use of nalbuphine, a mixed opioid agonist-antagonist, with entacapone, a catechol-O-methyltransferase (COMT) inhibitor, may increase the risk of opioid-related adverse effects, including respiratory depression and sedation, due to additive central nervous system depression. Entacapone can also inhibit the metabolism of catecholamines, potentially exacerbating opioid-induced constipation and urinary retention. Clinically, patients may experience enhanced sedation or respiratory compromise, particularly in elderly or debilitated populations."
"Concomitant use of clozapine and nalbuphine may potentiate central nervous system (CNS) depression, leading to additive sedative and respiratory depressant effects. Both drugs act on the CNS via distinct mechanisms but converge on common pathways, increasing the risk of hypotension, bradycardia, and profound sedation. Clinically, patients may experience excessive drowsiness, confusion, or respiratory compromise, particularly in those with pre-existing comorbidities or concurrent use of other CNS depressants."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CLOROTEKAL vs NALBUPHINE HYDROCHLORIDE, answered by our medical review team.
CLOROTEKAL is a Benzodiazepine Anxiolytic that works by Chlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the kidney, reducing sodium and chloride reabsorption, leading to increased diuresis and vasodilation.. NALBUPHINE HYDROCHLORIDE is a Opioid Agonist-Antagonist that works by Mixed agonist-antagonist at mu-opioid receptor; full agonist at kappa-opioid receptor; weak antagonist at mu-opioid receptor.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CLOROTEKAL and NALBUPHINE HYDROCHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CLOROTEKAL is: 500 mg orally every 8 hours for 7-14 days.. The standard adult dose of NALBUPHINE HYDROCHLORIDE is: 10-20 mg IM/IV/SC every 3-6 hours as needed; maximum single dose 20 mg, maximum daily dose 160 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CLOROTEKAL and NALBUPHINE HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CLOROTEKAL is classified as Category C. CLOROTEKAL is contraindicated in pregnancy. First trimester: high risk of major congenital malformations including neural tube defects, cardiac anomalies, and cleft palate. Second . NALBUPHINE HYDROCHLORIDE is classified as Category A/B. Pregnancy Category C. No adequate well-controlled studies in pregnant women. Animal studies have shown no teratogenic effects but embryocidal effects at high doses. Use only if pot. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.